July 09, 2008 - Allon Therapeutics Inc. (TSX: NPC), announced that it has been granted a United States patent covering composition, delivery and method of use for AL-309, the lead product candidate in the Company’s second neuroprotection technology platform, called Activity Dependent Neurotrophic Factor (ADNF). Gordon McCauley, President and CEO of Allon, said the Company plans to begin human clinical trials in 2009 to evaluate AL-309 as a treatment for peripheral neuropathy, a condition suffered by millions of people resulting from nerve damage that leads to pain, discomfort, numbness and muscle weakness. Among the major causes of neuropathy are diabetes and cancer chemotherapy... Allon Therapeutics' Press Release -
